**S. Table 5.** Meta-analysis of proportion of mortality among COVID-19 positive patients with AKI across different studies.

|  |  |  |  |
| --- | --- | --- | --- |
| **Study** | **Event/Sample size** | **Proportion (%) (95% CI)** | **Random Weight (%)** |
| **Deng, Y et al., 2020** | 20/20 | 100% (83.16% - 100%) | 6.12 |
| **Fisher, M et al., 2020** | 1,037/3,077 | 33.7% (32.03% - 35.4%) | 8.79 |
| **Gupte, S et al., 2020** | 356/948 | 37.55% (34.46% - 40.72%) | 8.73 |
| **Jamie, H et al., 2020** | 694/1,213 | 57.21% (54.37% - 60.02%) | 8.75 |
| **Jiahao, Z et al., 2020** | 7/37 | 18.92% (7.96% - 35.16%) | 7.09 |
| **Luo, X et al., 2020** | 43/57 | 75.44% (62.24% - 85.87%) | 7.60 |
| **Muner, M et al., 2020** | 80/161 | 49.69% (41.73% - 57.67%) | 8.34 |
| **Pei, G et al., 2020** | 19/22 | 86.36% (65.09% - 97.09%) | 6.28 |
| **Pelayo, J et al., 2020** | 42/110 | 38.18% (29.08% - 47.93%) | 8.14 |
| **Richardson, S et al., 2020** | 347/523 | 66.35% (62.12% - 70.39%) | 8.66 |
| **Ruan, Q et al., 2020** | 21/23 | 91.3% (71.96% - 98.93%) | 6.36 |
| **Xiao, G et al., 2020** | 12/55 | 21.82% (11.81% - 35.01%) | 7.56 |
| **Xu, S et al., 2020** | 19/56 | 33.93% (21.81% - 47.81%) | 7.58 |
| **Total (random effects)** | 2,697/6,302 | 54.24% (44.7% - 63.63%) | 100 |